Device and method for detection of metabolic syndrome biomarkers
Patent Information
- Application Number
- IN202621012783
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2026-02-05
- Publication Date
- 2026-10-07
- Estimated Expiration
- 2046-02-05
AI Technical Summary
Conventional diagnostic methods for metabolic syndrome require centralized laboratory testing, which is costly, time-consuming, and not suitable for resource-limited settings, and existing point-of-care devices struggle with multiplexed biomarker detection and subjective result interpretation.
A compact, integrated diagnostic device using paper-based microfluidics, automated spectral sensing, and AI-based analysis for multiplexed detection of metabolic syndrome biomarkers, featuring a microfluidic chip with hydrophobic barriers, stepper motor actuation, and spectral sensors for quantitative results.
Enables rapid, quantitative, and multiplexed detection of multiple metabolic syndrome biomarkers from a single serum sample, reducing resource requirements and minimizing subjectivity, suitable for resource-limited settings and improving clinical management.
Smart Images

Figure 00000028_0000 
Figure 00000029_0000 
Figure 00000030_0000
Abstract
Description
FIELD OF INVENTION
[0001] The present disclosure relates to diagnostic devices, and more particularly to a device and a method for detection of metabolic syndrome biomarkers.BACKGROUND OF INVENTION
[0002] Metabolic syndrome represents a cluster of co-occurring conditions that increase the risk for cardiovascular diseases and type 2 diabetes. These conditions include elevated blood glucose levels, abnormal lipid profiles, central obesity, hypertension, and increased uric acid concentrations. The prevalence of metabolic syndrome has been rising globally, affecting a substantial portion of adult populations in both developed and developing regions. Early and comprehensive diagnosis of metabolic syndrome is valuable for enabling timely intervention and management of associated health risks.
[0003] Conventional diagnostic approaches for metabolic syndrome typically involve laboratory-based testing that requires specialized equipment, trained personnel, and centralized facilities. Such testing often necessitates relatively large sample volumes and involves multiple separate assays to evaluate the various biomarkers associated with the syndrome. The time required for sample collection, transport to laboratories, processing, and result reporting can introduce delays in diagnosis and subsequent clinical decision-making. Additionally, the costs associated with traditional laboratory infrastructure and multiple individual tests can present barriers to widespread screening, particularly in resource-limited settings and primary healthcare environments.
[0004] Point-of-care testing (POCT) devices have emerged as alternatives to centralized laboratory testing, offering the potential for rapid results at or near the site of patient care. Paper-based microfluidic analytical devices, sometimes referred to as microfluidic paper-based analytical devices, represent one category of POCT platforms that leverage the inherent properties of cellulose substrates. Paper substrates can transport fluids through capillary action without external pumping mechanisms, and patterning techniques such as wax printing can define hydrophobic barriers to create channels and reaction zones. Such devices can be fabricated at relatively low cost and offer biodegradability advantages compared to polymer-based alternatives.
[0005] Colorimetric detection methods are commonly employed in paper-based diagnostic devices, wherein biochemical reactions produce visible color changes that correlate with analyte concentrations. Reading these colorimetric outputs can be performed through visual inspection, though such approaches may introduce variability and subjectivity in result interpretation. Smartphone-based imaging and analysis have been explored as means to improve quantification, though factors such as ambient lighting conditions and camera variations can affect measurement consistency.
[0006] Spectral sensing technologies offer capabilities for measuring absorbance or reflectance across wavelength ranges, potentially providing more detailed information about colorimetric reactions than single-point measurements or visual assessment. Integration of spectral sensing with automated positioning mechanisms can enable systematic data acquisition from multiple detection zones. Machine learning and artificial intelligence approaches have demonstrated utility in analyzing complex spectral data and predicting analyte concentrations based on trained models.
[0007] Current paper-based diagnostic platforms are frequently designed for the detection of single biomarkers, such as glucose monitoring for diabetes management. Multiplexed detection of multiple analytes from a single sample on an integrated platform remains an area of ongoing development. The combination of paper-based microfluidics, automated spectral sensing, and artificial intelligence-based data analysis in a unified device architecture for comprehensive metabolic syndrome biomarker profiling presents opportunities for advancement in point-of-care diagnostics. SUMMARY OF INVENTION
[0008] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0009] According to an aspect of the present disclosure, a device for detection of metabolic syndrome biomarkers is provided. The device includes a housing having a slot formed therein. The device includes a microfluidic chip removably disposed within the slot. The microfluidic chip has a cellulose substrate and a plurality of hydrophobic barriers formed on the cellulose substrate. The microfluidic chip defines at least one input zone to receive a serum sample containing a target analyte from among a plurality of metabolic syndrome biomarkers. The microfluidic chip defines a plurality of output zones having dried reagents corresponding to the plurality of metabolic syndrome biomarkers, and fluidically connected to the input zone. Each of the plurality of output zones is adapted to produce colorimetric reactions upon contact with the serum sample. The device includes an actuating unit disposed within the housing and mechanically coupled to the microfluidic chip. The actuating unit is adapted to actuate the microfluidic chip to sequentially position each of the plurality of output zones at a sensing location defined above the microfluidic chip. The device includes a sensing unit positioned above the sensing location, and configured to selectively acquire spectral data from each of the plurality of output zones across a predefined wavelength range corresponding to the colorimetric reactions when each of the plurality of output zones is sequentially positioned at the sensing location. The device includes a processor communicatively coupled to the sensing unit. The processor is configured to receive the spectral data from the sensing unit. The processor is configured to predict, using an Artificial Intelligence model, a concentration of the target analyte in the sample based on the spectral data. The processor is configured to detect presence of the metabolic syndrome biomarkers in the serum sample based on the predicted concentration of the target analyte.
[0010] This configuration provides a compact, integrated diagnostic platform that enables multiplexed detection of multiple metabolic syndrome biomarkers from a single serum sample. The combination of paper-based microfluidics with automated spectral sensing and AI-based analysis reduces the need for multiple separate tests, decreases sample volume requirements, and enables quantitative results without reliance on subjective visual interpretation. The removable microfluidic chip facilitates single-use operation that minimizes cross-contamination risks.
[0011] According to another aspect of the present disclosure, a method for detecting metabolic syndrome biomarkers is provided. The method includes depositing a serum sample containing a target analyte from among a plurality of metabolic syndrome biomarkers into an input zone of a microfluidic chip. The microfluidic chip is removably disposed within a slot formed in a housing. The method includes distributing the serum sample to a plurality of output zones fluidically connected to the input zone. The serum sample contacts dried reagents of the plurality of output zones to produce colorimetric reactions. The method includes selectively acquiring, using a sensing unit positioned above the microfluidic chip, spectral data from each of the plurality of output zones across a predefined wavelength range corresponding to the colorimetric reactions. The actuating unit is adapted to actuate the microfluidic chip to sequentially position each of the plurality of output zones at a sensing location to acquire the spectral data. The method includes predicting, using an Artificial Intelligence model, concentration of the target analyte based on the acquired spectral data. The method includes detecting a presence of the metabolic syndrome biomarkers in the serum sample based on the predicted concentration of the target analyte.
[0012] The foregoing general description of the illustrative embodiments and the following detailed description thereof are merely exemplary aspects of the teachings of this disclosure and are not restrictive.BRIEF DESCRIPTION OF FIGURES
[0013] Non-limiting and non-exhaustive examples are described with reference to the following figures.
[0014] FIG. 1 illustrates an isometric view of a diagnostic device, in accordance with an embodiment of the present disclosure;
[0015] FIG. 2 illustrates another isometric view of the device, in accordance with an embodiment of the present disclosure;
[0016] FIG. 3 illustrates a cross-sectional view of the device of FIG. 1 showing internal components, in accordance with an embodiment of the present disclosure;
[0017] FIG. 4A illustrates an isometric exploded view of an internal portion of FIG. 1, in accordance with an embodiment of the present disclosure;
[0018] FIG. 4B illustrates a side exploded view of the internal portion of FIG. 1, in accordance with an embodiment of the present disclosure; and
[0019] FIG. 5 illustrates a flowchart depicting a method for detecting the metabolic syndrome biomarkers using the device, in accordance with an embodiment of the present disclosure.DETAILED DESCRIPTION OF FIGURES
[0020] For the purpose of promoting an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings, and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated system, and such further applications of the principles of the invention as illustrated therein, being contemplated as would normally occur to one skilled in the art to which the invention relates. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skilled in the art to which this invention belongs. The system, methods, and examples provided herein are illustrative only and not intended to be limiting.
[0021] It will be understood by those skilled in the art that the foregoing general description and the following detailed description are explanatory of the invention and are not intended to be restrictive thereof.
[0022] Reference throughout this specification to "an aspect", "another aspect" or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present subject matter. Thus, appearances of the phrase "in an embodiment", "in another embodiment", and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
[0023] The terms "comprises", "comprising", or any other variations thereof, are intended to cover a non-exclusive inclusion, such that a process or method that comprises a list of steps does not include only those steps but may include other steps not expressly listed or inherent to such process or method. Similarly, one or more devices or sub-systems or elements or structures or components preceded by "comprises... a" does not, without more constraints, preclude the existence of other devices or other sub-systems or other elements or other structures or other components or additional devices or additional sub-systems or additional elements or additional structures or additional components.
[0024] FIG. 1 illustrates an isometric view of a device 100 for the detection of metabolic syndrome biomarkers in accordance with an embodiment of the present disclosure. The device 100 may be adapted to provide healthcare diagnostics in point-of-care testing environments. The device 100 may enable rapid and quantitative measurement of a plurality of metabolic syndrome biomarkers from a serum sample. Metabolic syndrome represents a cluster of co-occurring conditions that may increase risk for cardiovascular diseases and diabetes, and early detection of associated biomarkers may facilitate timely clinical intervention and personalized disease management.
[0025] The device 100 may be deployed in various healthcare settings. In some cases, the device 100 may be utilized in primary healthcare centers where access to laboratory infrastructure may be limited. The device 100 may also be deployed in clinics for routine patient screening and chronic disease monitoring. In wellness screening applications, the device 100 may enable preventive health diagnostics during health check-up camps or corporate wellness programs. The device 100 may further be deployed for remote diagnostics in geographically isolated areas where transportation of samples to centralized laboratories may be impractical. In resource-limited settings, the device 100 may provide an affordable diagnostic solution that reduces dependence on expensive laboratory equipment and trained personnel.
[0026] The device 100 may enable multiplexed detection of the plurality of metabolic syndrome biomarkers. In some cases, the plurality of metabolic syndrome biomarkers may include, but are not limited to, glucose, total protein, cholesterol, triglyceride, uric acid, and albumin. The device 100 may perform detection of all six biomarkers from a single serum sample, thereby reducing the number of separate tests and sample collections that may otherwise be required for comprehensive metabolic syndrome assessment.
[0027] Now, the construction details of the device 100 are discussed in detail in the forthcoming paragraphs.
[0028] The device 100 may include a housing 102 having a cylindrical configuration. The housing 102 may have a slot formed in one side of the housing 102. In an embodiment, the device 100 may include a tray that may extend partially outward from the slot formed in the housing 102.
[0029] The housing 102 may be fabricated using black polylactic acid (PLA) via three-dimensional (3D) printing. In some cases, the housing 102 may be fabricated with print settings of 0.2mm layer height and 100% infill for structural components. The housing 102 may be printed in enclosure mode to ensure opacity. The black PLA material may provide light-tight properties suitable for accurate spectral sensing operations performed within the device 100. The compact cylindrical form factor of the housing 102 may enable portability and ease of use in point-of-care diagnostic settings.
[0030] In some cases, the housing 102 may be fabricated, via black polylactic acid printing, of a material selected from at least one of acrylonitrile styrene acrylate (ASA), polyethylene terephthalate glycol (PETG), acrylonitrile butadiene styrene (ABS), nylon, and polycarbonate (PC). In an advantageous effect, the ASA may provide UV stability and weather resistance for outdoor or field deployment applications. In an advantageous effect, the PETG may provide chemical resistance and patient-contact safety. In an advantageous effect, the ABS may provide improved heat tolerance up to 80°C. In an advantageous effect, Nylon may provide flexible hinges and high toughness for mechanical components. In an advantageous effect, the Polycarbonate may provide high-strength properties for the housing 102. The material flexibility may enable scalable manufacturing while maintaining the compact, portable form factor of the device 100.
[0031] FIG. 2 illustrates another isometric view of the device 100, in accordance with an embodiment of the present disclosure. The tray may protrude from the slot formed in the housing 102. The tray may be slidably disposed within the slot and may be adapted to receive the microfluidic chip 104. The tray may include a pair of guide rails adapted to slide the microfluidic chip 104 within the housing 102. The pair of guide rails may provide alignment and support for the microfluidic chip 104 during insertion and removal operations. The tray may further include a tab portion extending outside the slot when the pair of guide rails is fully inserted within the slot. The tab portion may have a length of approximately 10 mm and may remain exposed outside the device 100 when the tray is fully inserted, thereby providing a gripping surface for a user to grasp and pull the tray for chip removal after testing is complete.
[0032] In an embodiment, the microfluidic chip 104 may be mounted on the tray. The microfluidic chip 104 may have a cellulose substrate 106 and a plurality of hydrophobic barriers formed on the cellulose substrate 106. The cellulose substrate 106 may include filter paper. In an exemplary scenario, the cellulose substrate 106 may include grade 1 Whatman filter paper. The grade 1 Whatman filter paper may provide a standardized medium for fluid transport and reagent immobilization. The plurality of hydrophobic barriers may be formed by wax printing on the cellulose substrate 106. The wax printing process may define hydrophobic and hydrophilic regions on the cellulose substrate 106 to control fluid flow pathways.
[0033] In an embodiment, the microfluidic chip 104 may define at least one input zone 108 configured to receive a serum sample containing a target analyte from among a plurality of metabolic syndrome biomarkers. The input zone 108 may be positioned at a central or proximal location on the microfluidic chip 104. The microfluidic chip 104 may further define a plurality of output zones 110 having dried reagents corresponding to the plurality of metabolic syndrome biomarkers. The plurality of output zones 110 may be fluidically connected to the input zone 108. In some cases, the microfluidic chip 104 may use a single input zone 108 that distributes to six output zones 110 in a radial or branching configuration. Each of the plurality of output zones 110 may be adapted to produce colorimetric reactions upon contact with the serum sample. The dried reagents may be pre-coated on the plurality of output zones 110.
[0034] The microfluidic chip 104 may include a plurality of hydrophilic channels extending from the input zone 108 to each of the plurality of output zones 110. The hydrophilic channels may be adapted to distribute, via capillary action, the serum sample from the input zone 108 to each of the plurality of output zones 110. The capillary action may enable passive fluid transport without external pumps or active fluid handling mechanisms. The hydrophilic channels may be defined by regions of the cellulose substrate 106 that are not covered by the hydrophobic barriers formed by wax printing. The branching configuration of the hydrophilic channels may enable uniform distribution of the serum sample to each of the plurality of output zones 110 from the single input zone 108.
[0035] Now, construction details of various components of the device 100 are discussed in detail in the forthcoming paragraphs in conjunction with FIGS. 3-4B
[0036] FIG. 3 illustrates a cross-sectional view of the device of FIG. 1 showing internal components, in accordance with an embodiment of the present disclosure. FIG. 4A illustrates an isometric exploded view of an internal portion of FIG. 1, in accordance with an embodiment of the present disclosure. FIG. 4B illustrates a side exploded view of the internal portion of FIG. 1, in accordance with an embodiment of the present disclosure. In an embodiment, the microfluidic chip 104 may be positioned in an upper portion of the internal cavity as a horizontal element that receives and processes fluid samples.
[0037] In an embodiment, the device 100 may include an actuating unit 112 that may be disposed within the housing 102 and mechanically coupled to the microfluidic chip 104. The actuating unit 112 may be a stepper motor that provides precise rotational movement for positioning the microfluidic chip 104. The actuating unit 112 may be adapted to actuate the microfluidic chip 104 to sequentially position each of the plurality of output zones 110 at a sensing location that may be defined above the microfluidic chip 104. In particular, the microfluidic chip 104 may be mounted on the actuating unit 112 such that rotation of the actuating unit 112 sequentially aligns each of the six output zones 110 at the sensing location. The actuating unit 112 may provide high step resolution with microstepping to enable accurate and repeatable rotational motion. The actuating unit 112 may maintain position without continuous feedback, which may simplify control and reduce power consumption.
[0038] In an embodiment, the device 100 may include a limit switch that may be disposed within the housing 102 and operatively connected to the actuating unit 112. The limit switch may be adapted to provide positional control for the actuating unit 112. The limit switch may enable homing of the actuating unit 112 to a known reference position upon initialization of the device 100. The device 100 may perform a self-test upon power-on before homing the actuating unit 112 via the limit switch. The limit switch may detect when the actuating unit 112 reaches a home position, thereby establishing a reference point for subsequent rotational movements.
[0039] Further, the device 100 may include a sensing unit 114 that may be positioned above the sensing location and above the microfluidic chip 104. In an exemplary scenario, the sensing unit 114 may be positioned at a distance of around 1 centimeter (cm) above the microfluidic chip 104. The sensing unit 114 may be configured to selectively acquire spectral data from each of the plurality of output zones 110 across a predefined wavelength range corresponding to the colorimetric reactions when each of the plurality of output zones 110 is sequentially positioned at the sensing location. In an exemplary embodiment, the sensing unit 114 may be a spectral sensor capable of measuring absorbance or reflectance spectra correlating with color changes at each detection zone. The spectral data may include one of absorbance and reflectance spectra across the predefined wavelength range of 400 Nanometer (nm) to 700 nm.
[0040] The sensing unit 114 may capture intensity across multiple wavelengths simultaneously, enabling concurrent detection of multiple biomarkers from a single optical path. The sensing unit 114 may provide high sensitivity and dynamic range to detect low-concentration analytes and resolve subtle absorbance or reflectance changes for accurate quantitation. The spectral sensor of the sensing unit 114 may include onboard reference channels or dark references for drift correction and improved long-term reproducibility. The on-board reference channels may simplify calibration procedures and may improve measurement stability over extended periods of operation.
[0041] In an embodiment, the device 100 may include a processor 116 that may be disposed within the housing 102 and communicatively coupled to the sensing unit 114. The processor 116 may be visible in a lower portion of the internal cavity of the housing 102. For example, the processor 116 is an ESP32 microcontroller with integrated Wireless Fidelity (Wi-Fi) and Bluetooth connectivity. The ESP32 microcontroller may provide a dual-core Central Processing Unit (CPU) with floating-point support for computational operations. In an embodiment, the integrated wireless connectivity of the processor 116 may enable data transfer, remote updates via over-the-air (OTA) firmware updates, and cloud integration. The processor 116 may support low-power modes, including deep sleep and real-time clock (RTC) support to extend battery life for portable operation of the device 100.
[0042] The processor 116 may be configured to receive the spectral data from the sensing unit 114. In an embodiment, the processor 116 may be configured to preprocess the spectral data to reduce noise and normalize intensity drift prior to the prediction. The preprocessing of spectral data may include baseline correction to remove background signal contributions that may arise from the cellulose substrate 106 or ambient light interference. The preprocessing may further include normalization to account for intensity drift that may occur due to variations in light source output or sensor response over time. The baseline correction may subtract a reference spectrum or apply polynomial fitting to remove systematic offsets from the measured spectral data. The normalization may scale spectral intensity values to a standardized range, thereby enabling consistent comparison across different measurement sessions and different microfluidic chips 104.
[0043] In an embodiment, the processor 116 may predict, using an Artificial Intelligence (AI) model, a concentration of the target analyte in the sample based on the spectral data. The AI model may include a machine learning regression model trained on spectral signatures and known analyte concentrations. In some cases, the machine learning regression model may include support vector regression. In some cases, the machine learning regression model may include random forest regression. In some cases, the machine learning regression model may include a neural network. The support vector regression model may map spectral features to concentration values using kernel functions that capture nonlinear relationships between absorbance patterns and analyte levels. The random forest regression model may aggregate predictions from multiple decision trees trained on different subsets of spectral features to improve prediction robustness. The neural network model may learn hierarchical representations of spectral data through multiple layers of interconnected nodes to capture complex spectral-concentration relationships.
[0044] The AI model may be trained on a dataset including spectral signatures acquired from serum samples with known analyte concentrations. The training dataset may include spectral measurements across the predefined wavelength range of 400 nm to 700 nm paired with reference concentration values determined by laboratory methods. The trained AI model may predict individual biomarker concentrations with enhanced sensitivity, specificity, and quantitativeness compared to threshold-based or visual inspection methods.
[0045] In an embodiment, the processor 116 may detect presence of the metabolic syndrome biomarkers in the serum sample based on the predicted concentration of the target analyte. The detection may involve comparing the predicted concentration values against reference ranges established for each biomarker. The processor 116 may classify each biomarker as within normal range, elevated, or reduced based on the predicted concentration relative to clinical thresholds.
[0046] In an embodiment, the processor 116 may be further configured to compute a metabolic syndrome risk score based on the predicted concentration of the target analyte. The metabolic syndrome risk score may aggregate the predicted concentrations of the plurality of metabolic syndrome biomarkers into a composite indicator of metabolic syndrome status. The risk score computation may weight individual biomarker contributions according to clinical significance or may apply classification algorithms to determine the overall metabolic syndrome risk category. The processor 116 may support the OTA firmware updates. Healthcare providers or device manufacturers may deploy the trained AI models, calibration parameters, or operational algorithms to the device 100 through wireless connectivity. The OTA update capability may simplify maintenance and may enable continuous improvement of the device 100 performance after deployment.
[0047] The processor 116 may include deep sleep and real-time clock (RTC) support to extend battery life for portable operation of the device 100. The deep sleep mode may reduce power consumption to minimal levels when the device 100 is not actively performing measurements. The RTC support may maintain time tracking during deep sleep periods, enabling scheduled wake-up for periodic operations or time-stamping of measurement results. The combination of deep sleep and RTC support may enable extended operation of the device 100 on battery power in field deployment scenarios where access to external power sources may be limited.
[0048] In an embodiment, the device 100 may include a Printed Circuit Board (PCB) 118, which may function as the primary electronic control and interface unit within device 100. The PCB 118 may be configured to provide electrical connectivity and operational control to the sensing unit 114 and actuating unit 112. The PCB 118 may incorporate circuitry for driving the actuating unit 112 that sequentially positions each of the plurality of output zones 110 of the microfluidic chip 104 at the predefined sensing location. Furthermore, the PCB 118 may supply regulated power to all connected components and enable communication with external devices through wired or wireless interfaces, thereby ensuring synchronized operation of mechanical, optical, and analytical subsystems within the device.
[0049] In an embodiment, the device 100 may include a wireless communication module may be electrically connected to the processor 116. The wireless communication module may be configured to transmit the predicted concentration to a remote device. The wireless communication module may utilize the Wi-Fi or Bluetooth connectivity provided by the processor 116. The results may be transmitted to connected systems for diagnostic interpretation using web servers. The wireless communication module may enable remote access to test results by healthcare providers or diagnostic systems. The transmission of predicted concentrations to remote devices may facilitate integration of the device 100 with electronic health record systems and cloud-based diagnostic platforms.
[0050] In various embodiments, the device 100 may include a visual indicator that may be mounted on an outer surface of the housing 102 and electrically coupled to the processor 116. The visual indicator may be adapted to indicate an operative status of the device 100. The operative status may include one of a chip insertion state, a test running state, and a chip removal state. In an embodiment, the visual indicator may include a Light-Emitting Diode (LED) or Liquid-Crystal Display (LCD). The LED or LCD may indicate "Chip inserted" when the microfluidic chip 104 is properly positioned within the slot. The LED or the LCD may indicate "Test running" during spectral data acquisition and processing operations. The LED or the LCD indicates "Remove chip" when testing is complete, and results are available. The visual indicator may provide feedback to a user regarding the current operational state of the device 100, thereby guiding user actions during the testing process.
[0051] FIG. 5 illustrates a flowchart depicting a method 500 for detecting the metabolic syndrome biomarkers using the device 100 in accordance with an embodiment of the present disclosure. The method 500 may begin with step 502 of depositing a serum sample containing the target analyte from among the plurality of metabolic syndrome biomarkers into the input zone 108 of the microfluidic chip 104. The microfluidic chip 104 may be removably disposed within the slot formed in the housing 102. The serum sample may have a volume of approximately 10-20 Microliter (gL) gL and may be micropipetted into the input zone 108. The microfluidic chip 104 may have the cellulose substrate 106 and the plurality of hydrophobic barriers formed on the cellulose substrate 106. The cellulose substrate 106 may include filter paper, and the hydrophobic barriers may be formed by wax printing on the cellulose substrate 106.The plurality of metabolic syndrome biomarkers may include glucose, total protein, cholesterol, triglyceride, uric acid, and albumin.
[0052] At step, the method 500 may include distributing the serum sample to the plurality of output zones 110 that may be fluidically connected to the input zone 108. The serum sample from the input zone 108 to the plurality of output zones 110 may be distributed via capillary action through the hydrophilic channels extending from the input zone 108 to the plurality of output zones 110. The serum sample may contact dried reagents of the plurality of output zones 110 to produce colorimetric reactions. The colorimetric reactions may be completed within the predefined time period of the serum sample contacting the dried reagents. In some cases, the predefined time period may be approximately 3 minutes. The dried reagents may be stable at room temperature and may be activated upon serum contact, enabling rapid assay completion.
[0053] Further, at step 506, the method 500 may include selectively acquiring, using the sensing unit 114 that may be positioned above the microfluidic chip 104, spectral data from each of the plurality of output zones 110 across the predefined wavelength range corresponding to the colorimetric reactions. The actuating unit 112 may be adapted to actuate the microfluidic chip 104 to sequentially position each of the plurality of output zones 110 at the sensing location to acquire the spectral data. The actuating unit 112 may be adapted to rotate the microfluidic chip 104 to align each of the plurality of output zones 110 at the sensing location. The sensing unit 114 may capture spectral intensity across multiple wavelengths corresponding to the colorimetric reactions produced at each of the plurality of output zones 110.
[0054] Thereafter, at step 508, the method 500 may include predicting, using the AI model, the concentration of the target analyte based on the acquired spectral data. Finally, at step 510, the method 500 may include detecting the presence of the metabolic syndrome biomarkers in the serum sample based on the predicted concentration of the target analyte. The detection may involve comparing the predicted concentration values against reference ranges established for each biomarker. The processor 116 may compile results from all six output zones 110 and may compute a metabolic syndrome risk score based on the predicted concentrations. The computed metabolic syndrome risk score may be displayed on the visual indicator or transmitted to the remote device via the wireless communication module.
[0055] Now, details of the dried agents are discussed in the forthcoming paragraphs.
[0056] For glucose detection, the dried reagents may include one of glucose oxidase, peroxidase, and a chromogenic substrate. In some cases, the chromogenic substrates for glucose detection may include o-dianisidine or 4-aminoantipyrine with phenol. When the target analyte is glucose, serum glucose may react with glucose oxidase. The glucose oxidase may catalyze glucose oxidation, producing gluconic acid and hydrogen peroxide (H2O2). In the presence of peroxidase, the H2O2 may oxidize the chromogenic substrates to form quinone-imine dye. The glucose detection may produce peak absorbance at approximately 505-550 nm wavelength.
[0057] For triglyceride detection, the dried reagents may include one of lipase, glycerol kinase, glycerol phosphate oxidase, peroxidase, and a chromogenic substrate. When the target analyte is triglyceride, serum triglycerides may be hydrolyzed by lipase. The lipase may liberate glycerol, which may undergo phosphorylation via glycerol kinase and oxidation via glycerol phosphate oxidase, yielding H2O2. The H2O2 may react with 4-aminoantipyrine and phenol in the presence of peroxidase to produce a red quinone-imine dye. The triglyceride detection may produce maximum absorbance near 540 nm wavelength.
[0058] For cholesterol detection, the dried reagents may include one of cholesterol esterase, cholesterol oxidase, peroxidase, and a chromogenic substrate. When the target analyte is cholesterol, cholesterol esters may be hydrolyzed by cholesterol esterase. Free cholesterol may be oxidized by cholesterol oxidase to generate H2O2. The H2O2 may couple with the chromogenic substrate in a peroxidase reaction, yielding a red dye. The cholesterol detection may produce absorption maxima at approximately 500-550 nm wavelength.
[0059] For total protein detection, the dried reagents may include copper (II) ions in an alkaline medium. When the target analyte is total protein, proteins in the serum sample may react with the copper (II) ions in the alkaline medium according to the Biuret method. Peptide bonds may form violet-colored coordination complexes with Cu2+ ions. The stable protein-copper complex may develop a characteristic coloration. The total protein detection using the Biuret method may produce maximum absorbance at a wavelength of around 540-550 nm.
[0060] For albumin detection, the dried reagents may include a dye selected from one of Bromocresol Green (BCG) and Bromocresol Purple (BCP). When the target analyte is albumin, albumin in the serum sample may react with the BCG or BCP dye in an acidic medium. The dye may bind to albumin selectively, forming a stable albumin-dye complex. The albumin-dye complex may exhibit green or blue coloration. The albumin detection using BCG may produce peak absorbance at approximately 630 nm wavelength. In some cases, the albumin detection using BCP may produce peak absorbance at approximately 603 nm wavelength.
[0061] For uric acid detection, the dried reagents may include one of uricase, peroxidase, and a chromogenic substrate. When the target analyte is uric acid, uric acid in the serum sample may be oxidized by uricase. The uricase reaction may produce allantoin and H2O2. The H2O2 may react with the chromogenic substrate, such as 4-aminoantipyrine and phenol, in a peroxidase reaction to generate a dye. The uric acid detection may produce strong absorbance near 520-550 nm wavelength.
[0062] Now, the advantages of the present disclosure are discussed in the forthcoming paragraphs.
[0063] The device 100 and the method 500 for detection of the metabolic syndrome biomarkers may provide multiplexed multi-biomarker detection from a single serum sample. The multiplexed detection capability may enable comprehensive metabolic syndrome assessment in one test, thereby improving clinical relevance compared to single-biomarker testing approaches. The detection of six biomarkers, including glucose, total protein, cholesterol, triglyceride, uric acid, and albumin from a single sample, may reduce the number of separate tests and sample collections that may otherwise be required. The comprehensive profiling capability may facilitate early diagnosis and personalized management of metabolic syndrome and related chronic diseases.
[0064] The device 100 may utilize low-cost paper-based fabrication leveraging wax printing techniques. The wax printing process may reduce resource requirements compared to conventional microfluidic fabrication methods that may require cleanroom facilities or specialized equipment. The paper-based fabrication approach may enable large-scale production of the microfluidic chip 104 at reduced per-unit cost. The cellulose substrate 106 may be manufactured using roll-to-roll printing or similar high-throughput processes, thereby enabling scalable manufacturing for widespread deployment. The low-cost fabrication may make the device 100 accessible for deployment in resource-limited healthcare settings where budget constraints may limit adoption of more expensive diagnostic technologies.
[0065] The motorized sensing unit 114 configuration may automate and standardize data acquisition during biomarker detection. The automated sequential scanning of output zones 110 may reduce human errors that may occur with manual visual inspection or manual positioning of sensing elements. The actuating unit 112 with stepper motor actuation may provide precise and repeatable positioning of each output zone 110 at the sensing location, thereby ensuring consistent spectral data acquisition across multiple tests and multiple devices. The automation may reduce operator training requirements and may enable consistent test performance regardless of operator skill level.
[0066] The processor 116 with AI regression prediction capability may provide high accuracy, sensitivity, and quantitative output delivery for biomarker concentration determination. The machine learning regression model may enhance detection performance compared to threshold-based or visual inspection methods that may be subject to subjective interpretation. The AI model may resolve subtle spectral variations that may correspond to clinically relevant concentration differences, thereby improving diagnostic sensitivity. The quantitative output may provide numerical concentration values rather than qualitative positive or negative results, enabling more precise clinical interpretation and longitudinal monitoring of biomarker levels over time.
[0067] The compact and portable design of the device 100 may be suited for deployment in remote, resource-limited, or primary care settings. The cylindrical form factor may enable easy transport and storage in clinical environments with limited space. The portable configuration may enable point-of-care testing at the patient location rather than requiring sample transport to centralized laboratory facilities. The battery-powered operation capability with low-power modes may enable extended operation in field deployment scenarios where access to external power sources may be limited.
[0068] The device 100 may utilize biodegradable materials that may minimize environmental impact compared to plastic point-of-care testing devices. The cellulose-based substrate 106 of the microfluidic chip 104 may be biodegradable and may decompose under environmental conditions without persisting as plastic waste. The paper-based microfluidic chip 104 may reduce biohazardous waste volume compared to larger plastic diagnostic cartridges. The use of biodegradable materials may align with sustainability objectives in healthcare settings seeking to reduce the environmental footprint of diagnostic operations.
[0069] While specific language has been used to describe the present subject matter, any limitations arising on account thereof are not intended. As would be apparent to a person in the art, various working modifications may be made to the method in order to implement the inventive concept as taught herein. The drawings and the foregoing description give examples of embodiments. Those skilled in the art will appreciate that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be split into multiple functional elements. Elements from one embodiment may be added to another embodiment.
Claims
1. A device (100) for detection of metabolic syndrome biomarkers, comprising: a housing (102) having a slot formed therein; a microfluidic chip (104) removably disposed within the slot, the microfluidic chip (104) having a cellulose substrate (106) and a plurality of hydrophobic barriers formed on the cellulose substrate (106), and defining: at least one input zone (108) to receive a serum sample containing a target analyte from among a plurality of metabolic syndrome biomarkers; and a plurality of output zones (110) having dried reagents corresponding to the plurality of metabolic syndrome biomarkers, and fluidically connected to the input zone (108), wherein each of the plurality of output zones (110) is adapted to produce colorimetric reactions upon contact with the serum sample; an actuating unit (112) disposed within the housing (102) and mechanically coupled to the microfluidic chip (104), the actuating unit (112) is adapted to actuate the microfluidic chip (104) to sequentially position each of the plurality of output zones (110) at a sensing location defined above the microfluidic chip (104); a sensing unit (114) positioned above the sensing location, and configured to selectively acquire spectral data from each of the plurality of output zones (110) across a predefined wavelength range corresponding to the colorimetric reactions when each of the plurality of output zones (110) is sequentially positioned at the sensing location; and a processor (116) communicatively coupled to the sensing unit (114), the processor (116) configured to: receive the spectral data from the sensing unit (114); predict, using an Artificial Intelligence (AI) model, a concentration of the target analyte in the sample based on the spectral data; and detect presence of the metabolic syndrome biomarkers in the serum sample based on the predicted concentration of the target analyte.
2. The device (100) as claimed in claim 1, wherein the housing (102) is fabricated, via black polylactic acid printing, of a material selected from at least one of acrylonitrile styrene acrylate, polyethylene terephthalate glycol, acrylonitrile butadiene styrene, nylon, and polycarbonate.
3. The device (100) as claimed in claim 1, wherein the housing (102) comprises: a tray slidably disposed within the slot, and adapted to receive the microfluidic chip (104), the tray comprises: a pair of guide rails adapted to slide the microfluidic chip (104) within the housing (102); and a tab portion extending outside the slot when the pair of guide rails is fully inserted within the slot.
4. The device (100) as claimed in claim 1, wherein the microfluidic chip (104) comprises a plurality of hydrophilic channels extending from the input zone (108) to each of the plurality of output zones (110), and wherein the hydrophilic channels are adapted to distribute, via capillary action, the serum sample from the input zone (108) to each of the plurality of output zones (110).
5. The device (100) as claimed in claim 1, wherein the hydrophobic barriers are formed by wax printing on the cellulose substrate (106), and wherein the cellulose substrate (106) comprises filter paper.
6. The device (100) as claimed in claim 1, wherein the dried reagents are precoated on the plurality of output zones (110).
7. The device (100) as claimed in claim 1, wherein the plurality of metabolic syndrome biomarkers comprises glucose, total protein, cholesterol, triglyceride, uric acid, and albumin.
8. The device (100) as claimed in claim 7, wherein: the dried reagents comprise one of glucose oxidase, peroxidase, and a chromogenic substrate when the target analyte is the glucose; the dried reagents for triglyceride comprise one of lipase, glycerol kinase, glycerol phosphate oxidase, peroxidase, and a chromogenic substrate when the target analyte is the triglyceride; the dried reagents comprise one of cholesterol esterase, cholesterol oxidase, peroxidase, and a chromogenic substrate when the target analyte is cholesterol; the dried reagents comprise copper (II) ions in an alkaline medium when the target analyte is total protein; the dried reagents comprise a dye selected from one of Bromocresol Green and Bromocresol Purple configured when the target analyte is the albumin; and the dried reagents for the uric acid comprise one of uricase, peroxidase, and a chromogenic substrate when the target analyte is the uric acid.
9. The device (100) as claimed in claim 1, wherein the spectral data comprises one of absorbance and reflectance spectra across the predefined wavelength range of 400 Nanometer (nm) to 700 nm.
10. The device (100) as claimed in claim 1, comprising: a limit switch disposed within the housing (102) and operatively connected to the actuating unit (112), the limit switch is adapted to provide positional control for the actuating unit (112).
11. The device (100) as claimed in claim 1, comprising: a visual indicator mounted on an outer surface of the housing (102) and electrically coupled to the processor (116), the visual indicator is adapted to indicate an operative status, wherein the operative status comprises one of a chip insertion, test running, and chip removal.
12. The device (100) as claimed in claim 1, wherein the processor (116) is disposed within the housing (102), the processor (116) is configured to: preprocess the spectral data to reduce noise and normalize intensity drift prior to the prediction.
13. The device (100) as claimed in claim 1, wherein the processor (116) is further configured to: compute a metabolic syndrome risk score based on the predicted concentration of the target analyte.
14. The device (100) as claimed in claim 1, comprising a wireless communication module electrically connected to the processor (116), the wireless communication module is configured to transmit the predicted concentration to a remote device (100).
15. A method (500) for detecting metabolic syndrome biomarkers, the method (500) comprising: depositing a serum sample containing a target analyte from among a plurality of metabolic syndrome biomarkers into an input zone (108) of a microfluidic chip (104), wherein the microfluidic chip (104) is removably disposed within a slot formed in a housing (102); distributing the serum sample to a plurality of output zones (110) fluidically connected to the input zone (108), wherein the serum sample contacts dried reagents of the plurality of output zones (110) to produce colorimetric reactions; selectively acquiring, using a sensing unit (114) positioned above the microfluidic chip (104), spectral data from each of plurality of output zones (110) across a predefined wavelength range corresponding to the colorimetric reactions, wherein the actuating unit (112) is adapted to actuate the microfluidic chip (104) to sequentially positioned each of the plurality of output zones (110) at a sensing location to acquire the spectral data; predicting, using an Artificial Intelligence (AI) model, concentration of the target analyte based on the acquired spectral data; and detecting a presence of the metabolic syndrome biomarkers in the serum sample based on the predicted concentration of the target analyte.
16. The method (500) as claimed in claim 15, wherein the microfluidic chip (104) has a cellulose substrate (106) and a plurality of hydrophobic barriers formed on the cellulose substrate (106).
17. The method (500) as claimed in claim 15, wherein the serum sample from the input zone (108) to the plurality of output zones (110) is distributed via capillary action through hydrophilic channels extending from the input zone (108) to the plurality of output zones (110).
18. The method (500) as claimed in claim 15, wherein the colorimetric reactions are completed within a predefined time period of the serum sample contacting the dried reagents.
19. The method (500) as claimed in claim 15, wherein acquiring the spectral data comprises acquiring one of absorbance and reflectance spectra across the predefined wavelength range of 400 Nanometer (nm) to 700 nm.
